Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | GRN | P28799 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.43 |
| ▸ | LAP3 | P28838 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838829 | 1.00 | CTSL (0.50) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL14550701 | 0.88 | CTSL (0.47) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL2840879 | 0.87 | CTSL (0.46) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL13744217 | 0.87 | CTSL (0.49) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL2840876 | 0.87 | CTSL (0.46) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL7280005 | 0.85 | TGFBR1 (0.44) | CTSLCTSBCTSSCTSKKMT2A | |
| SCHEMBL66243 | 0.84 | CTSL (0.66) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL17560 | 0.84 | CTSL (0.66) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL17559 | 0.84 | CTSL (0.66) | CTSLCTSBCTSSCTSKALDH1A1 | |
| Water SCHEMBL645995 | 0.83 | CTSS (0.68) | CTSLCTSBCTSSCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2241564-B1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARM CO LTD (JP) | 2014-04-30 | — | — | EP | disclosed |
| US-8501772-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20130012537-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8299255-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| CN-101939313-A | 3,8-diamino tetrahydroquinoline derivative | ZERIA PHARM CO LTD | 2011-01-05 | — | — | CN | disclosed |
| US-20100317693-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2241564-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012537-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | MC2R, GHRHR, REN | CTSL 2793/4885CTSB 3437/4885CTSS 3940/4885 |
| US-20100317693-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | GHSR, GHRHR, GNRHR | CTSL 3537/4885CTSB 3750/4885CTSS 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.